secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274082
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q3 net loss $43.2M; VOQUEZNA FDA approved for Erosive GERD; Dec launch
------------------------------------------------------------------------------

- Net loss $43.2M in Q3 2023 vs $51.1M in Q3 2022; includes $6.1M stock-based compensation.
- Cash $213.7M at Sep 30; $175M from revenue interest financing plus $100M Hercules loan available.
- FDA approved VOQUEZNA (vonoprazan) for Erosive GERD in Nov 2023; launch expected Dec 2023.
- NDA submitted for vonoprazan as daily Non-Erosive GERD treatment in Sep 2023; FDA action Q3 2024.
- Phase 3 As Needed NERD trial to start in 2024; cash expected to fund ops through end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/0001193125-23-274082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/d593359d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer